Trial0

Clinical trial · NCT07671937 · NOT_YET_RECRUITING · NA

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

Sponsor: University of Alabama at Birmingham

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.

Interventions

  • INSPIRE (INtegrating Systematic PatIent-Reported Evaluations) · BEHAVIORAL

    The INSPIRE intervention is the systematic capture and presentation of patient-reported outcomes (geriatric assessment, patient preferences, and distance to care) within multi-disciplinary tumor boards

  • Capture of patient-reported outcomes · BEHAVIORAL

    Capture of patient-reported outcomes including geriatric assessment and patient preferences

  • Enhanced Clinician Awareness · BEHAVIORAL

    Inclusion of patients within tumor board that may have patient-reported outcomes

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion/Exclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.

Inclusion Criteria:

* Inclusions Criteria- Patients:

  1. aged 18 years or older;
  2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;
  3. intention to be treated at a participating institution;
  4. with verbal fluency in English or Spanish; and
  5. scheduled to be discussed at MDTB.
* Inclusion criteria - Clinicians:

All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.

Exclusion Criteria:

* Exclusion criteria - Patients:

Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.

* Exclusion criteria - Clinician:

Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.

Sites (3)

  • University of Alabama at Birmingham, Birmingham, Alabama
  • University of California Los Angeles (UCLA), Los Angeles, California
  • University of Oklahoma (OU) Health Campus, Oklahoma City, Oklahoma

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-07-02.